Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

Abstract Background Combination CDK4/6 inhibitor and endocrine therapy has been shown to significantly improve progression‐free survival (PFS) in patients with hormone receptor (HR)‐positive, HER2‐negative metastatic breast cancer (mBC). The aim of this retrospective study was to evaluate the real‐w...

Full description

Bibliographic Details
Main Authors: James Sun, Xiaojun Zhong, Junjie Ma, Weihong Sun, Hyo S. Han, Hatem H. Soliman, Loretta S. Loftus, Ricardo L. B. Costa, Avan J. Armaghani, Aixa E. Soyano‐Muller, Brian J. Czerniecki, M. Catherine Lee, John V. Kiluk, Nazanin Khakpour, Susan J. Hoover, Christine Laronga, Hung T. Khong
Format: Article
Language:English
Published: Wiley 2021-11-01
Series:Cancer Medicine
Subjects:
absolute neutrophil count
endocrine therapy
metastatic breast cancer
neutropenia
neutrophil–lymphocyte ratio
palbociclib
Online Access:https://doi.org/10.1002/cam4.4295

Internet

https://doi.org/10.1002/cam4.4295

Similar Items